Clinical effects of probiotic bifidobacterium breve supplementation in adult patients with atopic dermatitis

Yonago Acta Medica

Volumn 53, Issue 2, 2010, Pages 37-45

  Yoshida, Yuichi ^a   Seki, Taizo ^b   Matsunaka, Hiroshi ^b   Watanabe, Tessin ^a   Shindo, Masahisa ^a   Yamada, Nanako ^a   Yamamoto, Osamu ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Research and Development   (Japan)

Author keywords

Allergy; Bifidobacterium; Intestinal; Probiotics; Quality of life

Indexed keywords

IMMUNOGLOBULIN E; PLACEBO; PROBIOTIC AGENT; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BIFIDOBACTERIUM; BIFIDOBACTERIUM BREVE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLOSTRIDIUM; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; ENTEROBACTERIACEAE; EOSINOPHIL COUNT; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE FLORA; MALE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PILOT STUDY; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77954876636     PISSN: 05135710     EISSN: 13468049     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Akiyama K, Hosono S, Takahashi E, Ishizeki S, Takigawa I, Imura S, et al. Effects of oral administration of Bifidobacterium breve on development of intestinal microflora in extremely premature infants. Acta Neonatol Jap 1994;30:130-137.
2. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133: 1433-1440.
3. Flöistrup H, Swartz J, Bergström A, Alm JS, Scheynius A, van Hage M, et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006;117:59-66.
4. Fukuhara S. Measuring HRQOL of patients with skin disease. Manual of DLQI and the Skindex29 Japanese version. Tokyo: Shorinsha; 2004.
5. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365-378.
6. Furue M, Saeki H, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al. Guidelines for management of atopic dermatitis. Nippon Hifuka Gakkai Zasshi 2009;119:1515-1534 (in Japanese with English abstract).
7. Hacini-Rachinel F, Gheit H, Le Luduec JB, Dif F, Nancey S, Kaiserlian D. Oral probiotic control skin inflammation by acting on both effector and regulatory T cells. PLoS One 2009;4:e4903.
8. Hattori K, Yamamoto A, Sasai M, Taniuchi S, Kojima T, Kobayashi Y, et al. Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. Arerugi 2003;52:20-30 (in Japanese).
9. He F, Ouwehand AC, Isolauri E, Hashimoto H, Benno Y, Salminen S. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 2001;30:43-47.
10. Hoarau C, Lagaraine C, Martin L, Velge-Roussel F, Lebranchu Y. Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J Allergy Clin Immunol 2006;117:696-702.
11. Hougee S, Vriesema AJM, Wijering SC, Knippels LMJ, Folkerts G, Nijkamp FP, et al. Oral treatment with probiotics reduces allergic symptoms in ovalbuminsensitized mice: a bacterial strain comparative study. Int Arch Allergy Immunol 2010;151:107-117.
12. Inoue Y, Iwabuchi N, Xiao JZ, Yaeshima T, Iwatsuki K. Suppressive effects of Bifidobacterium breve strain M-16V on T-helper type 2 immune responses in a murine model. Biol Pharm Bull 2009;32:760-763.
13. Iwabuchi N, Takahashi N, Xiao JZ, Yonezawa S, Yaeshima T, Iwatsuki K, et al. Suppressive effects of Bifidobacterium longum on the production of Th2-attracting chemokines induced with T cell-antigenpresenting cell interactions. FEMS Immunol Med Microbiol 2009;55:324-334.
14. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107:535-541.
15. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079.
16. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:1869-1871.
17. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008;122:8-12.
18. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
19. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008;121: 116-121.
20. Mitsuoka T. Human microbiota research-present and future. Chonai Saikingaku Zasshi 2005;19:179-192 (in Japanese with English abstract).
21. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2009;124:R2-R6.
22. Roessler A, Friedrich U, Vogelsang H, Bauer A, Kaatz M, Hipler UC, et al. The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin Exp Allergy 2008;38:93-102.
23. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389-395.
24. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
25. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80:S147-S171.
26. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259-1260.
27. Suzuki S, Shimojo N, Tajiri Y, Kumemura M, Kohno Y. A quantitative and relative increase in intestinal bacteroides in allergic infants in rural Japan. Asian Pac J Allergy Immunol 2008;26:113-119.
28. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
29. Tanabe S, Kinuta Y, Saito Y. Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. Int J Mol Med 2008;22: 181-185.
30. Tissier H. La réaction chromophile d'Escherich et le Bacterium coli. C R Soc Biol 1899;51:943-945.
31. Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y, et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 2003;111:587-591.
32. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-688.
33. Xiao JZ, Kondo S, Takahashi N, Odamaki T, Iwabuchi N, Miyaji K, et al. Changes in plasma TARC levels during Japanese cedar pollen season and relationships with symptom development. Int Arch Allergy Immunol 2007;144:123-127.